Zura Bio’s (ZURA) Neutral Rating Reiterated at HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 115.52% from the company’s current price.

A number of other brokerages have also recently weighed in on ZURA. Piper Sandler reissued an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Chardan Capital cut their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Leerink Partners initiated coverage on Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Down 2.5 %

NASDAQ:ZURA opened at $2.32 on Tuesday. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35. The stock has a 50-day simple moving average of $3.47 and a 200-day simple moving average of $3.66.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, equities analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

Insider Buying and Selling at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in Zura Bio by 777.1% in the 3rd quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after buying an additional 377,545 shares during the period. Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $2,999,000. State Street Corp boosted its stake in shares of Zura Bio by 47.5% in the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after buying an additional 127,300 shares in the last quarter. Finally, Braidwell LP acquired a new position in Zura Bio during the third quarter worth $10,040,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.